,22 To test whether this differential expression of BIRC5 and XIAP could be a vulnerability in MPN models, YM155, a pharmacological suppressant of survivin and XIAP (Figure 1D), was used in JAK2V617F-mutated cell lines. Here, XIAP is linked to myeloproliferative neoplasm.